U.S. justices block generic drug design defect lawsuits
WASHINGTON, June 24
WASHINGTON, June 24 (Reuters) - The U.S. Supreme Court ruled on Monday that makers of generic drugs already approved by the U.S. Food and Drug Administration cannot be held liable under state law for claims of design defects.
In a 5-4 vote, the court ruled for Mutual Pharmaceutical Co, a unit of URL Pharma, owned by Sun Pharmaceutical Industries .
- Police seek motive in fatal Washington state school shooting
- Two deputies killed, two others hurt in California shooting spree
- U.S. nurse quarantined over Ebola criticizes her treatment |
- Wall St. finally turning on Amazon as Bezos magic fades
- U.S., allies stage 22 air strikes in Iraq: U.S. Central Command